Skip to main content
Download PDF

Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report

BMC Pulmonary Medicine volume 19, Article number: 164 (2019) Cite this article

Abstract

Background

Burkholderia contaminans is one of the 20 closely related bacterial of the Burkholderia cepacia complex, a group of bacteria that are ubiquitous in the environment and capable of infecting people with cystic fibrosis (CF). This species is an emerging pathogen and it has been widely isolated from CF patients in Argentina, Spain, Portugal, Australia, Canada, USA with a low prevalence in Ireland, France, Russia, Switzerland, Czech Republic, and Italy. This is the first report of B. contaminans affecting two Italian CF patients attending the same CF Centre. We correlate B. contaminans colonisation with lung function decline and co-infection with other clinically relevant CF pathogens.

Case presentation

B. contaminans was identified by Multi Locus Sequence Typing in routine sputum analysis of two Caucasian CF women homozygous for Phe508del CFTR mutation. Sequence Type 102 was detected in both strains. It is known that B. contaminans ST102 was isolated both from CF and non-CF patients, with an intercontinental spread across the world. Random Amplified Polymorphic DNA analysis revealed the genetic relatedness between the two strains. We examined their susceptibility to antimicrobial agents, comparing the latter with that recorded for other B. contaminans isolated from different countries. We also described key virulence factors possibly linked with a clinical outcome. Specifically, we attempted to correlate colonization with the incidence of acute exacerbation of symptoms and lung function decline.

Conclusions

This case presentation suggests that acquisition of B. contaminans ST102 is not directly associated with a lung function decline. We retain that the presence of other CF pathogens (i.e. MRSA and Trichosporon) along with B. contaminans ST102 might have contributed to the worsening of clinical conditions in our CF patients. The circumstances leading to the establishment of B. contaminans ST102 infections are still unknown. We highlight the importance to proper detect and typing bacteria implicated in CF infection by using molecular techniques.

Peer Review reports

Background

Bacteria of the Burkholderia cepacia complex (BCC) are known opportunistic nosocomial pathogens causing severe respiratory infections in immunocompromised hosts and in Cystic Fibrosis (CF) patients [1]. BCC bacteria are associated with a poor prognosis, a rapid decline in lung function and reduced median survival [2]. Their heterogeneous intrinsic resistance to a wide range of antibiotics as well as their ability to develop further resistance during therapy make the treatment of BCC infections particularly difficult in CF [3]. The development of molecular tools has improved both the genetic characterization of cystic fibrosis transmembrane conductance regulator (CFTR) gene and the BCC taxonomy knowledge, properly identifying isolates at species and lineage level [4, 5]. Actually, the group is known to encompass at least 20 closely related species found in many niches of both natural and clinical environments, whose laboratory identification can often prove difficult [6,7,8,9,10,11].

Epidemiological studies examining relationships between respiratory infection and clinical outcomes have defined the contributions of BCC species to CF lung disease. Over the 20 formally named species within the complex, Burkholderia multivorans (genomovar II) and Burkholderia cenocepacia (genomovar III) together account for approximately 85–97% of all BCC infections in CF [12]. Although it has been well demonstrated that lung function declines more rapidly in CF patients infected with B. cenocepacia [12], also B. multivorans and Burkholderia dolosa have been associated with severe outcomes in CF [13,14,15,16]. Over the past several years, potential novel BCC species have been recovered with greater frequency from CF respiratory secretions but predicting prognosis after their infection in CF is challenging. Among the BCC species, a growing clinical interest concerns Burkholderia contaminans. Isolates of both clinical and environmental origin previously identified as taxon K and included in Multilocus Sequence Typimg (MLST) groups I and II, were identified as B. contaminans [9], referring to the metagenome that was recovered from the Sargasso Sea (the so-called Burkholderia SAR-1 metagenome) [17]. In addition to forest soil and river water [9], B. contaminans has been recovered from contaminated pharmaceutical products [9] and healthcare facilities where it has caused outbreaks [18, 19].

Over the past decade, B. contaminans is increasingly associated with CF [20] and with hospitalized non-CF patients [21, 22]. B. contaminans is frequently isolated from CF respiratory samples in Ibero-America countries [23, 24] indicating a large and characteristic geographic distribution of considerable concern. As reported in Multilocus Sequence Typing (MLST) database website, B. contaminans was also detected in Italy [25] and named as LMG 23253 (id: 126) and R-19218 (id: 2695) [9]. To date, there are no epidemiological studies that revealed the presence of other B. contaminans strains in Italy. We describe for the first time a single Centre experience of two CF patients in which the B. contaminans was recovered from the sputum sample and typed by means of MLST and Random Amplified Polymorphic DNA. To elucidate the potential clinical impact of B. contaminans, we aimed to describe its key virulence factors possibly linked with a clinical outcome. Specifically, we attempted to correlate colonization with the incidence of acute pulmonary exacerbation and lung function decline.

Case presentation

In May 2008 and in June 2008 two female CF patients were identified as B. contaminans positive at the Regional CF Centre of Policlinico Umberto I Hospital, Sapienza University of Rome, Italy, following MLST analysis as described by Baldwin et al. [5]. We collected demographic and clinical characteristics, chronic infections and CF comorbidity (pancreas insufficiency and CF-related diabetes) of both patients since they referred to our center. We also collected information on number of pulmonary exacerbations and exacerbation treatment in the preceding B. contaminans detection period and throughout the follow-up. Exacerbation events were ascertained through a review of electronic records and hospital charts.

Patient 1 was a Caucasian 32-year-old CF woman diagnosed with CF shortly after birth, due to meconium ileus, CFTR genotype Phe508del/Phe508del. The patient demonstrated good compliance with her treatment regimen, complicated by insulin dependent diabetes mellitus CF related. From the age of 2 years she was infected with Haemophilus influenzae 104 colony forming units (CFU)/ml, Sthaphylococcus aureus 104 CFU/ml, Stenotromonas malthophilia 104 CFU/ml, and Aspergillus flavus 104 CFU/ml. In 1992 aged 16 years, she acquired Methicillin-resistant Staphylococcus aureus (MRSA) 104 CFU/ml and became chronically infected. Her spirometry showed Forced Expiratory Volume in 1 s (FEV1) 2,47 L (72% of predicted) and Forced Vital Capacity (FVC) 3.01 L (78% of predicted). In August 2001, MRSA and a novel pathogen as Trichosporon 104 CFU/ml have been recovered in her respiratory secretions. At this time, her FEV1 dropped from 2,18 L (64% of predicted) to 1,48 L (48% of predicted) and her body mass index (BMI) was 19,2 kg/m2. In May 2008, patient attended the CF Centre for the annual review. Microbiological analyses of sputum samples identified for the first time the presence of B. contaminans 105 CFU/ml and showed also MRSA 106 CFU/ml, Achromobacter xylosoxidans 104 CFU/ml, Trichosporon spp. 105 CFU/ml. Patient’s FEV1 was 43%, her full blood count at the time showed a mildly elevated white cell count of 10.98 109/L, with neutrophil count of 4.69 109/L and C-reactive protein (CRP) of 10.9 mg/dL. In August 2008, the patient was admitted for pulmonary exacerbation and was treated with a course on intravenous ceftazidime 50 mg per kg per dose every 8 h and oral sulfamethoxazole-trimethoprim combined with physiotherapy. At the discharge her lung function did not improve with FEV1 1,21 L (40% of predicted) and FVC 1,86 L (52% of predicted). After 3 months she was admitted to hospital with poor nutritional status (BMI 18 kg/m2) and her FEV1 was 0,99 L (33% predicted), her lowest recorded. High resolution computed tomography (HRCT) showed severe bilateral bronchiectasis, mainly in the upper lobes with associated bronchial wall thickening and mucus retention in the bronchial lumen. Bilateral ground-glass opacity with areas of consolidation were also described (Fig. 1). It was decided to adopt a 2 weeks quadruple treatment strategy comprising IV ceftazidime 50 mg per kg per dose every 8 h, IV meropenem 40 mg per kg per dose, IV sulfamethoxazole-trimethoprim and chloramphenicol (500 mg every 6 h). Between January and July 2010, the patient required several hospital admissions for pulmonary exacerbations all of which were treated with a combination of IV meropenem 40 mg per kg per dose, IV tobramycin 300 mg once a day or IV Amikacin 500 mg bd, IV Linezolid 600 mg bd and IV Temocillin 2 g every 8 h. Oxygen supplementation was also started. In August 2010, the patient was admitted to hospital with acute dyspnea requiring increased oxygen supplementation and atrial fibrillation. A newsputum culture confirmed the presence of MRSA 104 CFU/ml, B. contaminans 106 CFU/ml and Trichosporon spp 106 CFU/ml. She started antimicrobial treatment with IV meropenem, IV tobramycin, IV ceftazidime, IV voriconazole 200 mg bd, IV methylprenisolone 20 mg bd and IV verapamil. Her condition continued to worsen over the following 3 days with an elevated CRP 50 g/dL. She died 48 h later due to lung failure.

Fig. 1
figure 1

High Resolution Computed Tomography (HRCT) of the Patient 1′ Lungs. A) Axial and B) Coronal HRCT images showing severe bilateral bronchiectasis, mainly in the upper lobes (black arrow), with associated bronchial wall thickening and mucus retention in bronchial lumen. Bilateral ground-glass opacity with areas of consolidation (white arrow)

Full size image

Patient 2 was a 34–year-old woman of Caucasian origin diagnosed with CF at the 1 year of age, due to respiratory symptoms. Her genotype is homozygous for the F 508del mutation. Between diagnosis and June 2008, the patient attended the Regional Cystic Fibrosis Centre in Rome, Italy. Her cough swabs and sputum cultures had yielded Streptococcus viridans 104 CFU/ml and S. aureus 106 CFU/ml. In 1984 she had also acquired, and had been treated for Pseudomonas aeruginosa 105 CFU/ml, which recurred in 1989,1995 and 1998. During the observation period, FEV1 and FVC were regularly recorded and remained stable over time (FEV1 3,12 L, 106% of predicted, FVC 3.4 L, 101% of predicted). Attempts to eradicate P. aeruginosa failed and she was deemed to be chronically infected in 1998. As the strain was sensitive to tobramycin following antibiotics susceptibility test, she was commenced on long-term anti-pseudomonal therapy comprising alternate months on-off of nebulised tobramycin twice daily. Since 1998 she was also chronically infected by MRSA 106 CFU/ml. Although she had good compliance with her medications and adherence to physiotherapy, her lung function started to decline. In 2004 patient experienced admission for treatment of pulmonary exacerbation and her lung function on discharge were FEV1 1,91 L (72% of predicted), FVC 2.43 L (79% of predicted), her lowest recorded. In June 2008, the patient presented for annual review and her FEV1was 1,7 L (65% of predicted), similar to previous annual review. MRSA was identified from her routine sputum sample. In addition, however, B. contaminans 105 CFU/ml was also detected, representing the second incidence in our Centre. Her sputum was positive to B. contaminans 104 CFU/ml again in December 2008 and to date it has never been detected. Between B. contaminans isolation and February 2017, the patient had experience two pulmonary exacerbation treated with oral antibiotics and both her nutritional status and pulmonary function remained stable. She commenced Lumacaftor/Ivacaftor therapy in February 2017. During the first year of treatment, the patient did not have exacerbations. Her last spirometry values increased with FEV1 2.12 L (87% of predicted) and FVC 2.69 L (92% of predicted).

In both cases, B. contaminans was isolated from sputum samples collected by the patients through spontaneous expectoration during routine visits at our CF Centre. Samples were routinely processed according to standard CF microbiological procedures [26]. Samples were liquefied by the addition of Sputasol (Oxoid Ltd. Hampshire) at a 1:1 dilution (v/v) and incubation at 37 °C for 1 h to reduce the viscosity of the sputum. Ten-fold dilutions of treated samples (20 μl) were plated and cultured on common appropriate media for CF pathogens including Burkholderia cepacia selective agar medium (BCSA) (Bio-Mérieux Marcy-l’Etoile, France). Plates were incubated at 35 °C for 24–48 h and then maintained at room temperature up to 5 days. The presumptive B. cepacia complex colonies were identified as BCC by API 20NE System (Bio-Mérieux Marcy-l’Etoile, France) and stored at − 80 °C. The identification of the bacterial isolate recovered from BCSA plates to the species status of B. contaminans was subsequently assessed following the BCC MLST scheme developed by Baldwin and colleagues [5]. Genomic DNA was extracted from a liquid pure culture using the cetyltrimethylammonium bromide (CTAB) method [27]. PCR reactions and conditions were performed as described by Baldwin and colleagues [5] for seven independent housekeeping loci (atpD, gltB, gyrB, recA, lepA, phaC, trpB) were amplified by PCR as described by Baldwin and colleagues [5]. The amplification products were purified using Sephadex G-100 resin according to Cesarini and collegues [28]. The nucleotide sequences of the seven amplified genetic loci were determined using nested primers as described previously [5]. Sequencing reactions were prepared by using Applied Biosystem Big Dye® Terminator sequencing kit version 3.1, according to the manufacturer’s instructions and analyzed with an ABI PRISM 310 Genetic Analyzer Perkin-Elmer, at the ENEA Genome Research Facility DNA Sequencing Laboratory (Genelab, ENEA C.R. Casaccia, Italy). The forward and reverse sequences of each locus were aligned, trimmed to the desired allele length using SeqMan II (DNAStar software) [28], and compared with existing alleles in the BCC MLST database at http://pubmlst.org/bcc/ [29], in order to assign the isolate allelic profile obtained with a sequence type (ST), indicative of each genetically distinct strain [5]. The taxonomic status of isolates was determined by ST searching against the MLST database [28]. The bacterial isolate of the Patient 1, named CF 349, resulted to have the Sequence Typing (ST) 102, showing the following allelic profile: atpD: 64; gltB: 80; gyrB: 76; recA: 89; lepA: 105; phaC: 97; trpB: 70. The bacterial isolate of the Patient 2, named CF 352, resulted to have the Sequence Typing (ST) 102 as that found for CF 349 strain, showing the following allelic profile: atpD: 64; gltB: 80; gyrB: 76; recA: 89; lepA: 105; phaC: 97; trpB: 70. The two bacterial isolates, CF 349 and CF 352, were genetically typed by random amplified polymorphic DNA (RAPD) analysis as described by Mahenthiralingam et al. [30]. RAPD fingerprints were analyzed using the Quantity One software package (Bio-Rad Laboratories, Milan, Italy) as previously described [28]. Reproducibility was verified by RAPD fingerprinting each isolate at least four times in independent experiments. CF349 and CF352 isolates were genetically related since they exhibited the same genetic fingerprints differing by no more than two bands (Fig. 2). Antibiotic susceptibility test of CF349 and CF352 isolates is presented in Table 1. It was studied by employing the Kirby-Bauer disc-diffusion method on Mueller Hinton II Agar (Bio-Merieux Marcy l’Etoile, France) as recommended by the Clinical and Laboratory Standards Institute (CLSI) [31]. The results were determined by measuring the diameter of complete inhibition of bacterial growth. Zone diameters of susceptibility testing results were categorized as sensitive (S), intermediate (I), or resistant (R) based on the CLSI breakpoint criteria for B. cepacia for ceftazidime (CAZ), meropenem (MEM), imipenem (IMP), trimethoprim/sulfamethoxazole (SXT), and breakpoint criteria for P. aeruginosa for piperacillin/tazobactam (TZP), amikacin (AK), aztreonam (ATM), Ciprofloxacin (CIP), gentamicin (GEN) and tobramycin (TOB).

Fig. 2
figure 2

Random amplified polymorphic DNA (RAPD) fingerprints of B. contaminans isolates generated using primer 270. Lane M, 123-bp molecular size marker ladder. On the left, B. contaminans, CF 349 strain, recovered from Patient 1 in May 2008. On the right, B. contaminans, CF 352 strain, recovered from Patient 2 in June 2008

Full size image
Table 1 Antibiotic resistance profile of B. contaminans CF349 and CF352 isolates
Full size table

Discussion

In this case report we described for the first time the genetic relationships between 2 B. contaminans isolates from two Italian CF patients attending the same CF Centre in the same period of time. We examined the clinical impact of this microorganism in two CF patients and the co-infection with other CF pathogens colonizing the patients’ respiratory tract. Strict infection control measures followed at the Regional CF Centre of Rome, Italy, including patient segregation, have reduced the epidemic spread but not eliminated new BCC infections, and CF patients may occasionally become infected by strains showing novel fingerprint types [32]. The present study reports the first case of B. contaminans acquisition in our CF Centre. MLST analysis performed on BCC strains collected from our patients did not reveal any other colonisation of B. contaminans during the outbreak period, in the previous years and up to date. This finding highlighted the continuing role of BCC species as opportunistic pathogens [33]. An accurate and rapid species identification within BCC is fundamental to manage BCC infections in CF patients in relation to appropriate therapy, infection control and lung transplantation. The development of molecular techniques, that has been improving knowledge in BCC taxonomy, enables to properly identify isolates that were previously difficult to be characterized, helping to individuate the strains responsible for novel acquisition [5]. The Burkholderia cepacia complex Multi Locus Sequence Typing website (https://pubmlst.org/bcc/) reveals the presence of 94 B. contaminans records and/or id, having 35 different STs. ST102 includes 20 strains isolated from environmental sources such as Sargasso sea [17], from sheep mastitis (milk) [34], and from human sources, including sputum and blood samples of CF and non-CF patients in North and South America, and Europe [25]. Some strains (AU7143 LMG23252) belonging to ST102 have been involved in widespread outbreaks in the United States and Brazil [25, 35]. Several cases of epidemic transmission of taxon K strains among CF patients have been reported in Italy [36], and in Portugal [37], and it is likely that environment may act as reservoir for novel BCC infections [38]. A positive selection of hypermutators, linked to antimicrobial resistance development, might be playing a key role in increasing B. contaminans adaptability to the CF-airway environment, facilitating the persistence of chronic lung infections [39]. As results of the segregation policies followed at the Regional Cystic Fibrosis Centre of Rome, CF patients harbour now unique BCC strains and the present study reports the first case of B. contaminans acquisition of closely-related strains by two patients. In the last few years, the potential clinical impact of infection with B. contaminans has been investigated [40]. There is evidence in CF that B. contaminans infections are often of transient nature [41] and thus can be perceived as respiratory tract colonization rather than true infection [40]. Only some patients develop chronic infection with long-term culture positivity [24]. However, some of the cases can get worse and result in fatalities.

The clinical experience about B. contaminans ST102 identified in our Centre was similar in both CF patients described in this report. Specifically, lung function decline and clinical deterioration were associated with the isolation of other CF pathogens along with B. contaminans. In effect, Patient 1 presented a deep decline of FEV1 and nutritional status in August 2001, when MRSA and a novel pathogen as Trichosporon spp. have been recovered in her respiratory secretions. At the time of first isolation of B. contaminans, lung function values did not change in comparison to those found 1 year before BCC colonization (FEV1 43% predicted vs 42% predicted and FVC 54% predicted vs 56%). While the contribution of MRSA to CF lung disease has been well defined, the potential pathogenicity of Trichosporon spp. was recently defined [42]. In agreement with Patient 1, Patient 2 showed a FEV1 decline in association with MRSA respiratory infection. Transient colonization of the respiratory tract by B. contaminans was not associated with changes in clinical outcome measures. Both CF patients showed a link between infection and disease when other pathogens were recovered from culture rather than B. contaminans isolation. At the time of B. contaminans detection, both Patient 1 and Patient 2 were attending the same adult CF clinic. After the identification of B. contaminans, we implemented the strategy focused on reducing cross-infection risk (either via direct exposures or surface contamination), and involved clinic sterilization, reinforcement of strict isolation practices and education of both members of the CF team and patients. Containment appeared to have been effective as B. contaminans has not been isolated in our CF Centre since.

In conclusion, our results suggest that acquisition of B. contaminans strain was not associated with a decline in lung function and highlight the feature that circumstances leading to the establishment of B. contaminans infections are still unknown. We retain that several factors such as patients’ clinical characteristics and other pathogens associated with CF pulmonary exacerbations, along with B. contaminans acquisition, might have contributed to the worsening of general conditions in our CF patients. This study demonstrates that B. contaminans infection can occur, probably due to the wide diffusion of this species in the environment. Our data also support an environmental/hospital origin of B. contaminans infections. The detection and accurate identification of the novel BCC species in CF specimens are fundamental for the analysis of the clinical response of CF individuals to BCC infection and are expected to have a significant impact on future clinical management in relation to appropriate therapy, infection control and lung transplantation.

Availability of data and materials

Data and material are available on reasonable request.

Abbreviations

BCC:

Burkholderia cepacia complex

CF:

Cystic fibrosis

FEV1:

forced expiratory volume in 1 second

FVC:

forced vital capacity

HRCT:

High resolution computed tomography

MLST:

Multilocus Sequence Typing

MRSA:

Methicillin-resistant Staphylococcus aureus

RAPD:

Random Amplified Polymorphic DNA

References

  1. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol. 2005;3:144–56.

    Article  CAS  Google Scholar 

  2. Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros. 2004;3:93–8.

    Article  CAS  Google Scholar 

  3. Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016;28:82–90.

    Article  Google Scholar 

  4. Lucarelli M, Porcaro L, Biffignandi A, Costantino L, Giannone V, Alberti L, et al. A new targeted CFTR mutation panel based on next-generation sequencing technology. J Mol Diagn. 2017;19(5):788–800. https://doi.org/10.1016/j.jmoldx.2017.06.002.

    Article  CAS  PubMed  Google Scholar 

  5. Baldwin A, Mahenthiralingam E, Thickett KM, Honeybourne D, Maiden MC, Govan JR, et al. Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J Clin Microbiol. 2005;43:4665–73. https://doi.org/10.1128/JCM.43.9.4665-4673.2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol. 2000;38:910–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Vermis K, Coenye T, Lipuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol. 2004;54:689–91. https://doi.org/10.1099/ijs.0.02888-0.

    Article  CAS  PubMed  Google Scholar 

  8. Vanlaere E, Lipuma JJ, Baldwin A, Henry D, de Brandt E, Mahenthiralingam E, et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol. 2008;58:1580–90. https://doi.org/10.1099/ijs.0.65634-0.

    Article  CAS  PubMed  Google Scholar 

  9. Vanlaere E, Baldwin A, Gevers D, Henry D, de Brandt E, LiPuma JJ, et al. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol. 2009;59:102–11. https://doi.org/10.1099/ijs.0.001123-0.

    Article  CAS  PubMed  Google Scholar 

  10. Peeters C, Zlosnik JE, Spilker T, Hird TJ, Lipuma JJ, Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol. 2013;36:483–9. https://doi.org/10.1016/j.syapm.2013.06.003.

    Article  PubMed  Google Scholar 

  11. de Smet B, Mayo M, Peeters C, Zlosnik JE, Spilker T, Hird TJ, et al. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. Int J Syst Evol Microbiol. 2015;65:2265–71. https://doi.org/10.1099/ijs.0.000251.

    Article  CAS  PubMed  Google Scholar 

  12. Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821–30. https://doi.org/10.1111/j.1469-0691.2010.03237.x.

    Article  CAS  PubMed  Google Scholar 

  13. Zahariadis G, Levy MH, Burns JL. Cepacia-like syndrome caused by Burkholderia multivorans. Can J Infect Dis. 2003;14(2):123–5. https://doi.org/10.1155/2003/675159.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Shafiq I, Carroll MP, Nightingale JA, Daniels TVW. Cepacia syndrome in a cystic fibrosis patient colonised with Burkholderia multivorans. BMJ Case Rep. 2011. https://doi.org/10.1136/bcr.08.2010.3296.

  15. Blackburn L, Brownlee K, Conway S, Denton M. “Cepacia syndrome” with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros. 2004;3:133–4. https://doi.org/10.1016/j.jcf.2004.03.007.

    Article  CAS  PubMed  Google Scholar 

  16. Kalish LA, Waltz DA, Dovey M, PotteryBynoe G, McAdam AJ, LiPuma JJ, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med. 2006;173:421–5. https://doi.org/10.1164/rccm.200503-344OC.

    Article  PubMed  Google Scholar 

  17. Venter JC, Remington K, Heidelberg JF, et al. Environmental genome shotgun sequencing of the sargasso sea. Science. 2004;304:66–74.

    Article  CAS  Google Scholar 

  18. Martin M, Christiansen B, Caspari G, Hogardt M, von Thomsen AJ, Ott E, et al. Hospital-wide outbreak of Burkholderia contaminans caused by prefabricated moist washcloths. J Hosp Infect. 2011;77(3):267–70. https://doi.org/10.1016/j.jhin.2010.10.004.

    Article  CAS  PubMed  Google Scholar 

  19. Moehring RW, Lewis SS, Isaacs PJ, Schell WA, Thomann WR, Althaus MM, et al. Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy. JAMA Intern Med. 2014;174(4):606–12. https://doi.org/10.1001/jamainternmed.2013.13768.

    Article  CAS  PubMed  Google Scholar 

  20. Bloodworth RA, Selin C, Lopez De Volder MA, Drevinek P, Galanternik L, Degrossi J, et al. Draft genome sequences of Burkholderia contaminans, a Burkholderia cepacia complex species that is increasingly recovered from cystic fibrosis patients. Genome Announc. 2015;3(4):e00766–15. https://doi.org/10.1128/genomeA.00766-15.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ohji G, Ohkusu K, Toguchi A, Otsuka Y, Hosokawa N, Iwata K. Burkholderia contaminans: unusual cause of biliary sepsis. J Infect Chemother. 2013;19(5):969–71.

    Article  Google Scholar 

  22. Peterson AE, Chitnis AS, Xiang N, Scaletta JM, Geist R, Schwartz J, et al. Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis. Am J Infect Control. 2013;41(12):1298–300. https://doi.org/10.1016/j.ajic.2013.05.015.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. 2015;21(2):150–6. https://doi.org/10.1016/j.cmi.2014.07.014.

    Article  CAS  PubMed  Google Scholar 

  24. Martina P, Bettiol M, Vescina C, Montanaro P, Mannino MC, Prieto CI, et al. Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J Clin Microbiol. 2013;51(1):339–44. https://doi.org/10.1128/JCM.02500-12.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mahenthiralingam E, Baldwin A, Drevinek P, Vanlaere E, Vandamme P, et al. Multilocus sequence typing breathes life into a microbial metagenome. PLoS One. 2006;1(1):e17. https://doi.org/10.1371/journal.pone.0000017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Smyth AR, Scott C, Bojcind S, Bryone M, Duff A, Flume P, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl. 1):S23–42.

    Article  Google Scholar 

  27. Giovannetti L, Ventura S, Bazzicalupo M, Fani R, Materassi R. DNA restriction fingerprint analysis of the soil bacterium Azospirillum. J Gen Microbiol. 1990;136:1161–6. https://doi.org/10.1099/00221287-136-6-1161.

    Article  CAS  PubMed  Google Scholar 

  28. Cesarini S, Bevivino A, Tabacchioni S, Chiarini L, Dalmastri C. RecA gene sequence and multilocus sequence typing for species-level resolution of Burkholderia cepacia complex isolates. Lett Appl Microbiol. 2009;49:580–8. https://doi.org/10.1111/j.1472-765X.2009.02709.

    Article  CAS  PubMed  Google Scholar 

  29. Jolley KA, Chan MS, Maiden MC. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinf. 2004;5:86. https://doi.org/10.1186/1471-2105-5-86.

    Article  CAS  Google Scholar 

  30. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol. 1997;35:808–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Clinical and Laboratory Standards Institute (CLSI) Performance standards for Antimicrobial Susceptibility Testing; Sixteen Informational supplement. 26 3:2006.

  32. Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol. 2008;104:1539–51. https://doi.org/10.1111/j.1365-2672.2007.03706.

    Article  CAS  PubMed  Google Scholar 

  33. Kenna DTD, Lilley D, Coward A, Martin K, Perry C, Pike R, et al. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. J Med Microbiol. 2017;66:490–501. https://doi.org/10.1099/jmm.0.000458.

    Article  PubMed  Google Scholar 

  34. Berriatua E, Ziluaga I, Miguel-Virto C, Uribarren P, Juste R, Laevens S, et al. Outbreak of subclinical mastitis in a flock of dairy sheep associated with Burkholderia cepacia complex infection. J Clin Microbiol 2001;39:990–994. doi: https://doi.org/10.1128/JCM.39.3.990-994.2001.

  35. Souza AV, Moreira CR, Pasternak J, Hirata Mde L, Saltini DA, Caetano VC, et al. Characterizing uncommon Burkholderia cepacia complex isolates from an outbreak in a haemodialysis unit. J Med Microbiol. 2004;53:999–1005. https://doi.org/10.1099/jmm.0.45702-0.

    Article  CAS  PubMed  Google Scholar 

  36. Campana S, Taccetti G, Ravenni N, Favari F, Cariani L, Sciacca A, et al. Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy. J Clin Microbiol. 2005;43:5136–42. https://doi.org/10.1128/JCM.43.10.5136-5142.2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cunha MV, Pinto-de-Oliveira A, Meirinhos-Soares L, Salgado MJ, Melo-Cristino J, et al. Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center. J Clin Microbiol. 2007;45:1628–33. https://doi.org/10.1128/JCM.00234-07.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vanlaere E, Coenye T, Samyn E, Van den Plas C, Govan J, De Baets F, et al. A novel strategy for the isolation and identification of environmental Burkholderia cepacia complex bacteria. FEMS Microbiol Lett. 2005;249:303–7. https://doi.org/10.1016/j.femsle.2005.06.026.

    Article  CAS  PubMed  Google Scholar 

  39. Martina P, Feliziani S, Juan C, Bettiol M, Gatti B, Yantorno O, et al. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. Int J of Med Microbiol. 2014;304(8):1182–91. https://doi.org/10.1016/j.ijmm.2014.08.011.

    Article  CAS  Google Scholar 

  40. Nunvar J, Kalferstova L, Bloodworth RAM, Kolar M, Degrossi J, Lubovich S, et al. Understanding the Pathogenicity of Burkholderia contaminans, an Emerging Pathogen in Cystic Fibrosis. PLOS ONE. 2016;11(8). https://doi.org/10.1371/journal.pone.0160975.

  41. Coutinho CP, Barreto C, Pereira L, Lito L, Melo Cristino J, Sá-Correia I. Incidence of Burkholderia contaminans at a cystic fibrosis center with an unusually high representation of Burkholderia cepacia during 15 years of epidemiological surveillance. J Med Microbiol. 2015;64:927–35. https://doi.org/10.1099/jmm.0.000094.

    Article  CAS  PubMed  Google Scholar 

  42. Esther CR Jr, Plongla R, Kerr A, Lin FC, Gilligan P. Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection. J Cyst Fibros. 2016;15(5):e45–9. https://doi.org/10.1016/j.jcf.2016.02.006.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the staff of the microbiology laboratory at Sapienza University of Rome, Policlinico Umberto I Hospital for their work in supporting treatment of the two patients in this case. They also thank Dr. Silvia Cesarini, Dr. Maite Sampedro and Dr. Cristina Cantale for their assistance in molecular analysis and figure preparation. The authors would like to express their gratitude to medical students Alessandro Porcella and Daniele Masia for the stimulating discussion we had on this case report.

Funding

This research was supported by grants from the Italian “Fondi regionali di ricerca”, Law 548/1993. The funders had no role in study design, data collection, analysis and interpretation of the data, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Public Health and Infectious Diseases, Adult Cystic Fibrosis Centre, “Sapienza” University of Rome, V.le Universita’ 37, 00185, Rome, Italy

    Daniela Savi & Paolo Palange

  2. Cystic Fibrosis Unit, Bambino Gesù Children’s Hospital, Rome, Italy

    Daniela Savi & Riccardo V. De Biase

  3. Dipartimento Materno Infantile e Scienze Urologiche, Sapienza University of Rome, Rome, Italy

    Serena Quattrucci

  4. Department of Public Health and Infectious Diseases, Laboratory of Microbiology, Policlinico Umberto I Hospital, Rome, Italy

    Maria Trancassini

  5. Department for Sustainability, Italian National Agency for New Technologies, Energy and Sustainable Economic Development, ENEA C.R Casaccia, 00123, Rome, Italy

    Claudia Dalmastri & Annamaria Bevivino

  6. Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

    Marta Maggisano

Authors
  1. Daniela Savi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serena Quattrucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Trancassini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Dalmastri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riccardo V. De Biase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marta Maggisano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Palange
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Annamaria Bevivino
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DS, SQ and PP were responsible for treating the patients; DS, SQ, and AB, recognised the novelty of the case and drafted the manuscript; DS, SQ, RDB, MM, and PP analyzed and interpreted the patient data; AB and CD was responsible for molecular analysis; MT was responsible for the microbiology analysis. All authors read, revised and approved the final manuscript.

Corresponding author

Correspondence to Daniela Savi.

Ethics declarations

Ethics approval and consent to participate

Ethical approval to report this case was not required.

Consent for publication

Written consent to publish was obtained from the next of kin of patients 1. Written consent to publish was obtained from patient 2. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Savi, D., Quattrucci, S., Trancassini, M. et al. Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report. BMC Pulm Med 19, 164 (2019). https://doi.org/10.1186/s12890-019-0923-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-019-0923-6

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us